Fate Therapeutics Inc $ 35.01 0.9 (2.64%)
Volume:
290,619
Avg Vol (1m):
803,454
Market Cap $:
3.04 Bil
Enterprise Value $:
2.59 Bil
P/E (TTM):
0.00
P/B:
6.41
Financial Strength | 5/10 |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| Cash-To-Debt | 6.58 | ||
| Equity-to-Asset | 0.73 | ||
| Debt-to-Equity | 0.17 | ||
| Debt-to-EBITDA | -0.71 | ||
| Piotroski F-Score | 3 | ||
| Altman Z-Score | 9.29 | ||
| Beneish M-Score | -0.83 | ||
| WACC vs ROIC | |||
Profitability Rank | 1/10 |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| Operating Margin % | -903.76 | ||
| Net Margin % | -881.86 | ||
| ROE % | -43.68 | ||
| ROA % | -32.04 | ||
| ROC (Joel Greenblatt) % | -219.86 | ||
| 3-Year Revenue Growth Rate | 4.1 | ||
| 3-Year EBITDA Growth Rate | -12.3 | ||
| 3-Year EPS without NRI Growth Rate | -11.1 |
Valuation Rank |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| PB Ratio | 6.39 | ||
| PS Ratio | 200.04 | ||
| EV-to-EBIT | -22.21 | ||
| EV-to-EBITDA | -22.72 | ||
| EV-to-Revenue | 195.9 | ||
| Current Ratio | 11.92 | ||
| Quick Ratio | 11.92 | ||
| Days Sales Outstanding | 47.44 |
Dividend & Buy Back |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -22.3 |
Valuation & Return |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| Price-to-Tangible-Book | 6.41 | ||
| Price-to-Intrinsic-Value-Projected-FCF | 102.97 | ||
| Earnings Yield (Greenblatt) % | -4.5 |